Evommune, Inc. (EVMN) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$5.30

From 52W high−83.31%

Volume422636.00

Market cap$191.26M

P/E (TTM)—

P/S (TTM)19.1x

Div yield—

Key dataOct 19, 2026

Open

$5.30

From 52W high

−83.31%

Volume

422636.00

Market cap

$191.26M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.0x

P/E (TTM)

—

RSI (14)

19.5

MomentumView details →

1D Return

+1.93%

YTD Return

−69.01%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.0x

EV/Sales

−0.1x

P/S (TTM)

19.1x

P/B (TTM)

0.7x

ProfitabilityView details →

Gross Margin

96.51%

Net Margin

−946.68%

EBITDA Margin

−957.79%

ROE (TTM)

−34.10%

ROA (TTM)

−31.35%

Asset Turnover

0.03x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+61.25%

EPS CAGR 3Y

+3.96%

EBITDA YoY

—

MomentumView details →

1D Return

+1.93%

YTD Return

−69.01%

1Y Return

—

RSI (14)

19.5

vs 50D SMA

−48.66%

vs 200D SMA

−71.07%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

11.68x

Quick Ratio

11.68x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.89

EPS Surprise

−33.94%

Beats (12Q)

1/12

Next Q EPS Est

−$0.91

Avg Surprise (4Q)

−236.12%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

10.00M

Net Income (TTM)

−94.67M

Op. CF (TTM)

−74.15M

Latest newsMore news →

Evommune's phase IIb clinical trial for EVO756 in chronic spontaneous urticaria failed to meet its primary endpoint.112d ago

Similar companies

Akebia Therapeutics, Inc.AKBA Entrada Therapeutics, Inc.TRDA PepGen Inc.PEPG Sutro Biopharma, Inc.STRO Compugen Ltd.CGEN CAMP4 Therapeutics CorporationCAMP Find similar companies →

Latest newsMore news →

Evommune's phase IIb clinical trial for EVO756 in chronic spontaneous urticaria failed to meet its primary endpoint.112d ago